BPTS
Closed
Biophytis
7.03
+0.12 (+1.74%)
Last Update: 27 Jun 2024 16:30:00
Yesterday: 6.91
Day's Range: 7.03 - 7.03
Send
sign up or login to leave a comment!
When Written:
4.3
Biophytis is a clinical-stage biotechnology company that is focused on the development of novel therapies for age-related diseases. The company is headquartered in Paris, France, and has a research and development center in Cambridge, Massachusetts.
Biophytis is developing a pipeline of drug candidates that target the molecular mechanisms of aging, with the goal of treating a range of age-related diseases such as sarcopenia, obesity, and diabetes. The company's lead drug candidate, Sarconeos, is currently in Phase 2 clinical trials for the treatment of sarcopenia, a condition characterized by the loss of muscle mass and strength that occurs with aging.
In addition to Sarconeos, Biophytis is developing a pipeline of other drug candidates, including Macuneos for the treatment of age-related macular degeneration, and Plasmin for the treatment of diabetic retinopathy.
Biophytis is also collaborating with a number of academic institutions and pharmaceutical companies to advance its drug development programs. The company has received funding from various sources, including the European Union, the French government, and private investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Biophytis is developing a pipeline of drug candidates that target the molecular mechanisms of aging, with the goal of treating a range of age-related diseases such as sarcopenia, obesity, and diabetes. The company's lead drug candidate, Sarconeos, is currently in Phase 2 clinical trials for the treatment of sarcopenia, a condition characterized by the loss of muscle mass and strength that occurs with aging.
In addition to Sarconeos, Biophytis is developing a pipeline of other drug candidates, including Macuneos for the treatment of age-related macular degeneration, and Plasmin for the treatment of diabetic retinopathy.
Biophytis is also collaborating with a number of academic institutions and pharmaceutical companies to advance its drug development programs. The company has received funding from various sources, including the European Union, the French government, and private investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!